Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/29/2025

Treatment of Chronic Rhinosinusitis with Saline and HOCl

Introduction to Guidelines

  • The European Position Paper on Rhinosinusitis (EPOS 2020) recommends saline irrigation as an important aspect of treatment for chronic rhinosinusitis (CRS) due to its established safety, low cost, and adequate efficacy 3, 4
  • The European Position Paper on Rhinosinusitis (EPOS 2020) presents a head-to-head comparison of HOCl versus saline for chronic rhinosinusitis treatment, citing a single double-blind placebo-controlled trial (Yu 2016) comparing low-concentration HOCl to saline in 43 CRS patients 1, 2

Efficacy and Safety of Saline and HOCl

  • HOCl significantly reduced symptom scores at 2 and 4 weeks compared to saline in a double-blind placebo-controlled trial of 43 CRS patients 1
  • No differences in other outcomes, such as endoscopy scores and disability indices, were found between HOCl and saline in the same trial 1
  • No treatment-related adverse events were reported for either HOCl or saline solution in the trial 1

Clinical Recommendations

  • The European Position Paper on Rhinosinusitis (EPOS 2020) does not recommend HOCl over saline for CRS treatment despite positive symptom findings, likely due to the limited evidence base from a single study 1, 3, 4
  • Saline remains the first-line recommendation for nasal irrigation in rhinosinusitis due to its safety, low cost, and adequate efficacy 3, 4
  • The modest symptom improvement with HOCl does not justify routine adoption over saline for CRS treatment 1

Gaps in Evidence

  • Only one randomized controlled trial (RCT) directly compares the effectiveness of HOCl and saline solutions for rhinosinusitis treatment 1
  • No studies have examined the impact of HOCl or saline on morbidity, mortality, or long-term quality of life outcomes in CRS patients 1
  • The existing trial only measured symptom scores over a short period of 4 weeks, highlighting the need for longer-term studies 1